Transfer of technology and know-how for the production of pandemic-related health products in the...
A version of this brief was published on 13 June '25 by the Graduate Institute as part of their 'Governing Pandemic Snapshot' series: https://www.governingpandemics.org/gp-snapshot
During...
The EU proposed Covid waivers of certain TRIPS rules are mostly meaningless
Since October 2020, discussions have been ongoing at the World Trade Organization’s Trade-Related Aspects of Intellectual Property Rights (TRIPS) Council about a waiver of...
The Role of Activism in Shaping Law and Policies that Support Access to Medicines
This article is also available as a PDF here.
Almost 26 years ago, here in Amsterdam, on November 25-26, 1999, Health Action International, Médecins Sans...
Pharmaceutical patents and data exclusivity in an age of AI-driven drug discovery and development
This is an excerpt from a longer report on AI, medicines development and the patent system.
Download the full report here (or by clicking...
The European Commission says Covid-19 vaccines should be global public goods, but do their...
The European Commission has entered into advance purchase agreements (APAs) for Covid-19 vaccines with six pharmaceutical companies and is concluding negotiations with two companies....
Ensuring that intellectual property rights aren’t a barrier to scaling-up: the remarkable example of...
This week various international bodies are tackling different challenges in meeting the urgent problem of scaling-up manufacture of and access to vaccines for Covid-19....
Proposed TRIPS waiver a hollow diplomatic compromise with little practical impact
In October of 2020, 9 months into the pandemic, fearing conflicts over intellectual property (IP) related to medical measures to fight the pandemic, India...
Brazil’s Federal Court Reviews Medicines Mailbox Patents
This week the media reported that the Brazilian federal court removed the patent protection for eculizumab, sold under the brand name Soliris by Alexion...
How patents, data exclusivity and SPCs interact to extend market exclusivity of medicines: the...
Patents usually confer 20-year exclusive rights on inventions. Data exclusivity laws confer, depending on the country, 5 to 10 years’ exclusive rights over safety...
European Parliament’s amendments make the Regulation for EU-wide compulsory licensing difficult to use and...
European Parliament legislative resolution of 13 March 2024, on the proposal for a regulation of the European Parliament and of the Council on compulsory...